Highlights
- Annual statistical report on progress of patients in the iTrack™ Global Data Registry (iTrack™ Registry) was released this month
- 409 eyes, followed for 12 months with an 85% success rate in patients with baseline intraocular pressure (IOP) greater than 18 mmHg
- Minimal complications reported across more than 600 eyes in the Registry
Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company) is pleased to announce positive outcomes from the iTrack™ Registry, reinforcing the clinical effectiveness and safety of canaloplasty with iTrack™ in real-world practice.
About the iTrack™ Registry
Established in 2022, the iTrack™ Registry is an independently managed database into which surgeons contribute clinical data from their iTrack™ surgeries.
Currently 20 surgeons from 20 sites around the world are contributing surgical cases, and this number is growing. To date, the iTrack™ Registry has captured data from more than 600 eyes. The 2025 statistical report is significant because 409 eyes have now reached 12-month follow-up.
The data in the iTrack™ Registry is prospective.
The importance of the iTrack™ Registry to Nova Eye Medical
The iTrack™ Registry provides robust, real-world, prospective evidence of surgery outcomes in routine clinical practice. It meets the Company’s objectives to:
- Drive broader surgical adoption of iTrack™ because it enables the identification of meaningful clinical trends and supports the development of evidence-based treatment protocols.
- Validate clinical outcomes and provides strong support for market access, payor engagement, surgeon education and training.
Clinical highlights of the iTrack Registry 2025 statistical report
Patients experienced a mean 40% reduction in medication burden across the cohort, underscoring the procedure’s potential to reduce long-term dependence on pharmacological therapy. Notably, the success rate in IOP reduction in patients with baseline intraocular pressure (IOP) greater than 18 mmHg increased was 85%.
There were only six reported adverse events, including a spontaneously self-resolving Descemet’s membrane detachment in one eye (0.3%), and postoperative (temporary, selfresolving) hyphema involving more than 10% of the anterior chamber reported in five eyes (1.2%) within the cohort.
These outcomes are considered clinically meaningful when compared with other minimally invasive glaucoma surgery (MIGS) procedures, highlighting canaloplasty with iTrack’s ability to deliver durable IOP reduction with a favourable safety profile.
Future iTrack Registry Activities
The iTrack™ Registry will continue to collect data and we expect the increase of cohort in the registry will demonstrate the strong safety and efficacy of iTrack™ in real world treatment.
The passage of 12 months follow up has opened the opportunity for surgeons to extract data, collate the outcomes and prepare journal articles for peer review and publication.
Read our ASX Announcement here: iTrack™ Registry Clinical Data Update
For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com
About us:
Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma.
The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure.
With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.
For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com
Contact details:
Company
Tom Spurling
Managing Director
+61 417 818 658
[email protected]
Investors
Mark Flynn
Investor Relations
+61 416 068 733
[email protected]
